XML 147 R24.htm IDEA: XBRL DOCUMENT
v3.19.3.a.u2

OTHER EXPENSE (INCOME), NET | 12 Months Ended
--- | ---
Dec. 31, 2019
Other Income and Expenses [Abstract] |
OTHER EXPENSE (INCOME), NET | OTHER EXPENSE (INCOME), NET Other expense (income), net for the years 2019, 2018 and 2017 consists of:
(in millions) |  | 2019 |  | 2018 |  | 2017
Gain on the Skincare Sale |  | $ | — |  |  | $ | — |  |  | $ | (309 | )
Gain on the iNova Sale |  | — |  |  | — |  |  | (309 | )
Gain on the Dendreon Sale |  | — |  |  | — |  |  | (97 | )
Loss on the Sprout Sale |  | — |  |  | — |  |  | 98 |
Net (gain) loss on other sales of assets |  | (31 | ) |  | 6 |  |  | 37 |
Litigation and other matters |  | 1,401 |  |  | (27 | ) |  | 226 |
Acquired in-process research and development costs |  | 41 |  |  | 1 |  |  | 5 |
Acquisition-related costs |  | 8 |  |  | 1 |  |  | — |
Other, net |  | (5 | ) |  | (1 | ) |  | 1 |
Other expense (income), net |  | $ | 1,414 |  |  | $ | (20 | ) |  | $ | (348 | )
In 2019, Litigation and other matters of $1,401 million includes the settlement of a legacy U.S. securities class action matter (which is subject to final court approval). In 2018, Litigation and other matters of $27 million includes a favorable adjustment of $40 million related to the Salix legacy litigation matter. In 2017, Litigation and other matters of $226 million includes: (i) $96 million related to the settlement of the Allergan shareholder class actions, (ii) $93 million related to the settlement of the Solodyn® antitrust class actions litigation and (iii) $20 million related to the Mimetogen Pharmaceuticals litigation. These matters and other significant matters are discussed in further detail in Note 21, "LEGAL PROCEEDINGS". In 2019, Net (gain) loss on other sales of assets includes $20 million related to the achievement of a milestone related to a certain product. In 2019, Acquired in-process research and development costs includes $38 million of in-process research and development costs associated with the upfront payments to enter into certain exclusive licensing agreements.

X
- References No definition available. + Details
Name: | us-gaap_OtherIncomeAndExpensesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 720 -URI http://asc.fasb.org/topic&trid=2122503 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 610 -URI http://asc.fasb.org/topic&trid=49130413 + Details
Name: | us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration